Microdose, Author at Microdose

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

19 Feb 2021

Mindset Pharma Added to North American Psychedelics Index

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

18 Feb 2021

REPEAT — Pure Extracts and Canada House Wellness Group sign agreement to distribute concentrate products through existing provincial distribution channels

VANCOUVER, British Columbia, Feb....

By Microdose

Press Releases

18 Feb 2021

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD VANCOUVER, BC, Feb....

By Microdose

Press Releases

18 Feb 2021

Pure Extracts and Canada House Wellness Group sign agreement to distribute concentrate products through existing provincial distribution channels

VANCOUVER, British Columbia, Feb....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

17 Feb 2021

Psychedelic Partnership Reached, Ehave Inc. and Brain Scientific Sign Memorandum of Understanding to Map Brain Response to Psychedelic Treatment, Collaborate in the Development of Neural Net Algorithms for the Psychedelic Mental Health Sector, E-Tattoo Technology is Expected to Provide Continuous Monitoring

By Microdose

Press Releases

17 Feb 2021

Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap’s Mental Health Technology

DENVER, Feb....

By Microdose

Press Releases

17 Feb 2021

Psyched Wellness Closes $6,603,000 Bought Deal Private Placement

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

17 Feb 2021

Revive Therapeutics Acquires Unique Psilocybin Assets

TORONTO, Feb....

By Microdose

Press Releases

17 Feb 2021

MindMed’s LSD Neutralizer Study Begins

Potential Emergency Off-Switch for Psychedelic Assisted Therapies BASEL, SwitzerlandFeb....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

No Result

View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.